Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00351728
First received: July 12, 2006
Last updated: July 5, 2016
Last verified: July 2016
  Purpose
Patients diagnosed with ocular melanoma consent to participate in the study. Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in the first year. Subsequently, these combined scans will be performed at 6-monthly intervals for a total of two combined scans per year.

Condition
Ocular Melanoma
Choroidal Melanoma
Uveal Melanoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 174
Study Start Date: June 2006
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
choroidal melanoma patients
Criteria

Inclusion Criteria:

  1. Patients with a diagnosis of ocular melanoma (a pigmented malignant tumor) involving the choroid and/or ciliary body (the blood vessel layer in the back of the eye and/or the part of the eye behind the iris).
  2. Patients 18 years of age or older.
  3. Patients able to give informed consent.

Exclusion Criteria:

  1. Patients who refuse to participate in the study.
  2. Patients who are unable to cooperate with or cannot undergo PET/CT scanning.
  3. Patients who will be moving out of the area of UCLA during the ten years of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351728

Locations
United States, California
Jules Stein Eye Institute
Los Angeles, California, United States, 90095-7000
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: Tara A McCannel, MD, PhD Jules Stein Eye Institute, UCLA
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00351728     History of Changes
Other Study ID Numbers: UCLA IRB #05-04-016 
Study First Received: July 12, 2006
Last Updated: July 5, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on September 27, 2016